Marshall Wace’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Marshall Wace’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,400	Closed	-$240K	–	3551
2025 Q3	$240K	Buy	+2,400	New	+$216K	﹤0.01%	2514
2024 Q3	–	Sell	-311,000	Closed	-$28.8M	–	3008
2024 Q2	$28.8M	Buy	311,000 +165,300	+113%	+$14.8M	0.04%	390
2024 Q1	$13.2M	Sell	145,700 -463,900	-76%	-$43M	0.02%	653
2023 Q4	$54.4M	Sell	609,600 -440,300	-42%	-$32.7M	0.09%	221
2023 Q3	$76.7M	Buy	1,049,900 +572,200	+120%	+$45.7M	0.16%	126
2023 Q2	$39.7M	Sell	477,700 -186,700	-28%	-$15.6M	0.08%	273
2023 Q1	$50.6M	Buy	664,400 +295,600	+80%	+$24.5M	0.11%	209
2022 Q4	$30.6M	Sell	368,800 -1,080,600	-75%	-$87.5M	0.07%	323
2022 Q3	$115M	Buy	1,449,400 +1,428,800	+6,936%	+$120M	0.25%	73
2022 Q2	$1.53M	Buy	+20,600	New	+$1.55M	﹤0.01%	2177
2021 Q4	–	Sell	-333,300	Closed	-$41.9M	–	4331
2021 Q3	$41.9M	Buy	333,300 +14,600	+5%	+$1.88M	0.17%	108
2021 Q2	$43.2M	Buy	318,700 +296,400	+1,329%	+$39M	0.2%	90
2021 Q1	$3.02M	Buy	+22,300	New	+$3.34M	0.01%	1111

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Marshall Wace's XBI Position: Q4 2025 in Review

Marshall Wace sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2025, closing a stake of 34,292 shares — an estimated $3.44M sold.

Marshall Wace first reported a position in XBI in Q1 2017 and held it in 18 quarters. The position peaked at $18.3M in Q4 2017. 813 funds tracked by Wall St. Rank hold XBI as of Q4 2025.

Marshall Wace reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2025 after selling out during the quarter.
Marshall Wace sold 34,292 State Street SPDR S&P Biotech ETF shares in Q4 2025, an estimated $3.44M.
Marshall Wace first reported a position in State Street SPDR S&P Biotech ETF in Q1 2017 and held it in 18 quarters.
Marshall Wace's State Street SPDR S&P Biotech ETF position peaked at $18.3M in Q4 2017.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2025.

Based on Marshall Wace's 13F filing for Q4 2025, filed 13 Feb 2026.